Tag: patient centred glaucoma care

Selected Work in Glaucoma | Dr Shibal Bhartiya

Glaucoma is not simply a disease of elevated eye pressure. It is a chronic optic neuropathy driven by structural vulnerability, mitochondrial dysfunction, metabolic and vascular factors, delayed diagnosis, treatment burden, and the silent accumulation of irreversible optic nerve damage over decades.

The published work of Dr Shibal Bhartiya addresses this broader understanding of glaucoma. Her peer-reviewed research — indexed on PubMed and spanning more than 25 years of clinical and academic practice — examines glaucoma as a long-arc disease requiring stewardship, longitudinal monitoring, individualized risk assessment, and patient-centred care.

This page summarises her key research themes with selected PubMed-indexed publications in each area.

View all indexed publications on PubMed | Google Scholar | ORCID 0000-0002-1947-5474

Research Themes

Glaucoma as a Neurodegenerative and Systemic Disease {#neuro}

Optic nerve damage in glaucoma can continue even when intraocular pressure is controlled. This has driven a significant shift in glaucoma thinking — from pressure reduction alone toward preservation of retinal ganglion cell health, mitochondrial function, and long-term neuronal survival. Published work by Dr Bhartiya in this area explores neuroprotective strategies, the biology of optic nerve aging, and the expanding connections between glaucoma and systemic metabolic disease.

Niacinamide and Neuroprotection: The Glaucoma Holy Grail Bhartiya S. Journal of Current Glaucoma Practice. 2022;16(3):141–143. PMID 36793265 | DOI: 10.5005/jp-journals-10078-1390

This editorial examines the emerging role of niacinamide (Vitamin B3) as a neuroprotective agent in glaucoma. It reviews the evidence linking mitochondrial NAD+ depletion to retinal ganglion cell death, and evaluates whether dietary niacinamide supplementation may slow optic nerve loss independently of intraocular pressure.

Reversing Aging and Improving Health Span in Glaucoma Patients: The Next Frontier? Dada T, Mahalingam K, Bhartiya S. Journal of Current Glaucoma Practice. 2024;18(3):87–93. View on PubMed

This paper positions glaucoma within the science of aging and healthspan. It reviews retinal ganglion cell degeneration as an age-related process and examines emerging strategies — including mitochondrial support, cellular senescence pathways, and anti-aging interventions — for preserving optic nerve health beyond IOP control.

GLP-1 Receptor Agonists, Allostatic Load, and Reframing the Glaucoma Paradigm Bhartiya S, Dorairaj SK. Journal of Current Glaucoma Practice. 2025;19(1):1–2. PMID 41523176 | DOI: 10.5005/jp-journals-10078-1471

Co-authored with Prof Syril Dorairaj (Mayo Clinic, Jacksonville), this editorial argues that GLP-1 receptor agonists — widely used in diabetes and obesity — may offer neuroprotective and IOP-lowering effects in glaucoma through mechanisms including reduced allostatic load, retinal ganglion cell rescue, and mitochondrial protection. It calls for a reframing of glaucoma management to incorporate emerging evidence on systemic metabolic pathways.

Intraocular Pressure, Progression, and Target IOP {#iop}

Lowering IOP remains the foundation of glaucoma management, but IOP is neither uniform across the day nor reliably predictive of individual progression risk. Published work in this area examines the concept of target IOP, the clinical significance of 24-hour pressure fluctuation, and the challenge of managing patients who progress despite apparently controlled pressures.

New Perspectives on Target Intraocular Pressure Clement CI, Bhartiya S, Shaarawy T. Survey of Ophthalmology. 2014. PMID 25081325

This paper critically evaluates existing frameworks for setting target IOP — percentage reduction, predetermined figures, and calculated ranges — and concludes that none have been adequately validated. It argues for individualized, patient-specific target-setting based on structural vulnerability and lifetime disease risk.

24-Hour Intraocular Pressure Monitoring: The Way Ahead Bhartiya S, Gangwani M, Kalra RB, Aggarwal A, Gagrani M, Sirish KN. Journal of Current Glaucoma Practice. 2020. PMID 31915728

Diurnal IOP fluctuation is an independent risk factor for glaucoma progression. This paper reviews the clinical evidence for 24-hour IOP monitoring and its implications for managing patients in whom single time-point clinic measurements may miss clinically significant pressure peaks — particularly those who progress despite apparently normal IOPs.

Minimally Invasive Glaucoma Surgery (MIGS) and Surgical Decision-Making {#migs}

The landscape of glaucoma surgery has changed significantly. MIGS has expanded options for patients and surgeons, but it has also introduced new questions around patient selection, long-term efficacy, and how conventional surgery should now be evaluated and positioned.

Revisiting Results of Conventional Surgery: Trabeculectomy, Glaucoma Drainage Devices, and Deep Sclerectomy in the Era of MIGS Bhartiya S, Dhingra D, Shaarawy T. Journal of Current Glaucoma Practice. 2019;13:45–49. PMID 31564792

This paper examines how trabeculectomy, glaucoma drainage devices, and deep sclerectomy should be assessed against MIGS alternatives — arguing that conventional surgery remains essential for advanced disease while MIGS expands the earlier surgical window for appropriate patients.

Evaluating Glaucoma Surgeries in the MIGS Context Dhingra D, Bhartiya S. Romanian Journal of Ophthalmology. 2020;64(2):85–95. PMID 32685772

A structured review of how glaucoma surgeries should be evaluated for real-world efficacy, highlighting the chronic, asymptomatic nature of glaucoma as a complicating factor in both patient decision-making and meaningful outcome measurement.

Surgical Management of Glaucoma: Evolving Paradigms Shaarawy T, Bhartiya S. Indian Journal of Ophthalmology. 2011;59(Suppl1):S123–130. PMID 21150024

An early and widely cited framework for glaucoma surgical decision-making, co-authored with Prof Tarek Shaarawy (University of Geneva). This paper outlines the core goals of surgical intervention — minimal complications, precise IOP titration, long-term pressure control — and surveys the therapeutic options available to the glaucoma surgeon.

Pars Plana Ahmed Glaucoma Valve Implantation with Triamcinolone-Assisted Vitrectomy in Refractory Glaucomas Dada T, Bhartiya S, Vanathi M, Panda A. Journal of Glaucoma. 2010. PMID 20689206

Original research reporting surgical outcomes of glaucoma drainage device implantation in refractory cases, demonstrating sustained IOP reduction at both 6 and 12 months post-operatively.

GATT: Gonioscopy-Assisted Transluminal Trabeculotomy {#gatt}

Gonioscopy-assisted transluminal trabeculotomy (GATT) is an ab interno angle surgery that removes the trabecular meshwork and inner wall of Schlemm’s canal circumferentially — targeting the primary site of outflow resistance in glaucoma. Published work by Dr Bhartiya examines the evidence base for GATT, its mechanisms, patient selection, and its place within the evolving surgical hierarchy for glaucoma.

Is GATT the Answer? Bhartiya S, Aktas Z, Ichhpujani P. Journal of Current Glaucoma Practice. 2023;17(4):167–168. PMID 38269261 | DOI: 10.5005/jp-journals-10078-1425

This editorial evaluates GATT’s mechanism — circumferential cleavage of the trabecular shelf to open the collector system — and asks whether the evidence supports its expanded use across glaucoma subtypes. It examines both the rationale for GATT’s efficacy and the critical considerations around irreversibility, patient selection, and the downstream consequences of destroying the entire trabecular meshwork.

MIGS, Health Economics, and the Equity Imperative {#migs-equity}

The adoption of minimally invasive glaucoma surgery is not only a clinical decision — it is an economic and ethical one. MIGS devices are expensive, their cost-effectiveness varies across healthcare systems, and access to newer surgical technologies is deeply unequal globally. Published work by Dr Bhartiya addresses this gap directly, arguing that surgical innovation must be evaluated not only for efficacy but for its distributional consequences.

Minimally Invasive Glaucoma Surgeries, Health Economics, and the Moral Imperative of Equity in Glaucoma Care Bhartiya S, Zhang X, Perera S. Journal of Current Glaucoma Practice. 2025;19(3):103–106. PMID 41113786 | DOI: 10.5005/jp-journals-10078-1489

Co-authored with Prof Xiulan Zhang (Zhongshan Ophthalmic Centre, Sun Yat-sen University) and Prof Shamira Perera (Singapore National Eye Centre, Duke-NUS), this editorial makes an explicit ethical argument: that the promise of MIGS cannot be realized if access is determined by economic geography rather than clinical need. It calls for health-economic evaluation frameworks that account for real-world affordability and equity — particularly in high-burden, resource-variable settings across Asia and beyond.

Quality of Life and the Lived Experience of Glaucoma {#qol}

Glaucoma affects far more than measurable visual field scores. Treatment fatigue, fear of progression, reduced mobility, loss of independence, and the psychological weight of a chronic invisible disease all shape how patients live with and manage their condition. Research in this area argues that glaucoma outcomes must be measured not only by optic nerve parameters but by functional independence and daily quality of life.

Weighted Quality of Life in Glaucoma Patients with Advanced Disease Bhartiya S, Ichhpujani P, Kapoor S, Parmar UPS, Singh D, Kumar S. Journal of Current Glaucoma Practice. 2025;19(2):85–89. PMID: 41113687

This observational pilot study (n=37 patients with moderate to severe glaucoma) compared standard GQL-15 quality of life scores with patient-weighted assessments capturing how much individuals actually value each visual domain. Patients prioritized recognizing faces and finding dropped objects — findings with direct implications for how clinicians communicate disability, set treatment goals, and evaluate success.

Patient Centricity and the Ethics of Glaucoma Care Bhartiya S. Journal of Current Glaucoma Practice. 2020;14(2):68–71. PMID 33304063

In a chronic asymptomatic disease with multiple acceptable treatment arms, patient-centred care is not a preference — it is a clinical requirement. This review examines shared decision-making, risk-benefit analysis, adherence, and the ethics of patient participation in glaucoma management.

Complementary Approaches and Evidence Appraisal {#cam}

Patients with glaucoma frequently explore complementary approaches alongside conventional treatment, particularly when progression continues despite controlled pressures. Published work in this area applies scientific scrutiny to alternative strategies without dismissing patient interest in them.

Complementary and Alternate Management of Glaucoma: The Verdict So Far Bhartiya S, Ichhpujani P. Journal of Current Glaucoma Practice. 2014;8(2):54–57. PMID 26997809

This review evaluates the evidence base for complementary approaches in glaucoma — including yoga, acupuncture, and nutritional supplements such as Ginkgo biloba. It argues that future research must evaluate these approaches not only for IOP effects, but for objective structural and functional outcomes including OCT and visual field parameters.

Genetics and Precision Medicine in Glaucoma {#genetics}

The future of glaucoma care includes identifying at-risk individuals before irreversible damage occurs. Published work in this area examines hereditary risk, family screening, and the practical and ethical challenges of translating genetic knowledge into clinical glaucoma counselling.

Bridging Genomics and Practice: Rethinking Genetic Counseling in Glaucoma Bhartiya S, Aggarwal A, Dada R. Journal of Current Glaucoma Practice. 2025;19(4):155–157. View on JCGP

This editorial argues that genetic counselling in glaucoma has not kept pace with the science. It examines hereditary risk patterns, the clinical implications of emerging genomic tools, and how glaucomatologists can integrate predictive medicine into practical, patient-centred counselling without oversimplifying polygenic risk.

Healthcare Systems, Drug Prescribing, and Continuity of Care {#systems}

Glaucoma outcomes are shaped not only by biology and surgery, but by the healthcare systems through which patients are diagnosed and treated. Disruptions in care continuity — from a pandemic, uneven prescribing patterns, or access constraints — translate directly into delayed diagnosis and preventable vision loss.

Glaucoma Drug Prescription Pattern in North India: Public vs Private Sector Hospitals Bhartiya S, Ichhpujani P, Parmar UPS et al. Journal of Current Glaucoma Practice. 2024;18(1):16–22. PMC10997958

The first comparative pharmacoepidemiological study of glaucoma prescribing across public and private hospitals in North India. Findings document significant variation in drug choice, fixed-dose combination use, and generic prescribing — with direct implications for treatment access, cost burden, and long-term adherence in resource-variable settings.

Generics versus Brand-Named Drugs for Glaucoma: The Debate Continues Bhartiya S et al. Romanian Journal of Ophthalmology. 2020;64(3):239–244. PMID 33367157

Glaucoma requires lifelong medication. The cost, efficacy, and side-effect profile of prescribed drugs directly determine whether patients take them consistently. This review examines the clinical implications of generic versus brand-name prescribing, with attention to treatment sustainability and adherence in the Indian context.

Current Glaucoma Practice: The Covid-19 Impact Bhartiya S. Journal of Current Glaucoma Practice. 2020;14(1):1–2. PMID 32581461

Published at the onset of the pandemic, this editorial documents the immediate and structural impact of Covid-19 on glaucoma care delivery — reduced clinic capacity, deferred surgery, and the urgent need to build more resilient systems for chronic disease monitoring and continuity.

Evolution of Glaucoma Research: A Scientometric Review Ichhpujani P, Kalra G, Kaur R, Bhartiya S. Journal of Current Glaucoma Practice. 2020;14(3):98–105. PMID 33867758

A bibliometric analysis mapping the global trajectory of glaucoma research — identifying dominant research themes, most productive institutions, and emerging areas of scientific inquiry across two decades of indexed publications.

Tackling Glaucoma Blindness: A Public Health Perspective {#blindness}

Glaucoma is responsible for a significant proportion of irreversible global blindness. Prevention requires not only clinical excellence but coordinated public health effort — early detection programs, community screening, equitable access to care, and the integration of telemedicine and AI into scalable glaucoma systems.

Current Perspectives in Tackling Glaucoma Blindness Bhartiya S, Ichhpujani P, Wadhwani M et al. Indian Journal of Ophthalmology. 2025;73(Suppl 2):S189–S196. PMID 41113687 | DOI: 10.4103/IJO.IJO_3280_23

This comprehensive narrative review, with Dr Bhartiya as corresponding author from Marengo Asia Hospitals, covers the full spectrum of measures required to address glaucoma blindness. It examines pharmacological innovation, novel drug delivery systems, MIGS, personalized medicine and genetic profiling, lifestyle modifications, telemedicine, and AI integration — alongside community-based detection programs and public health policy.

Editorial and Academic Leadership

Dr Bhartiya serves as Executive Editor of the Journal of Current Glaucoma Practice — the official, PubMed-indexed journal of the International Society of Glaucoma Surgery — and as Editor-in-Chief of Clinical and Experimental Vision and Eye Research (CLEVER).

In these roles she has shaped peer-reviewed discourse on glaucoma diagnostics, surgical outcomes, neuroprotection, chronic disease management, metabolic connections to glaucoma, and the ethics of long-term patient care. She has edited 28 textbooks across glaucoma, perimetry, and ophthalmic surgery, published with Jaypee Brothers, Springer, and other medical publishers.

Academic Profiles

Verified scholarly records are maintained across the following indexed profiles:

Clinical Philosophy

Glaucoma is rarely a single-moment diagnosis.

It is a disease of cumulative risk, silent structural damage, and long-term uncertainty. Most patients retain good central vision for years while progressive optic nerve loss occurs quietly in the periphery. By the time symptoms appear, significant irreversible damage has often already occurred.

The goal of glaucoma management is therefore not simply to lower a pressure number. It is to preserve vision, functional independence, mobility, and quality of life across the lifespan — through early recognition, individualized risk assessment, longitudinal monitoring, and consistent continuity of care.

This is long-arc stewardship. It is the governing principle across the clinical and academic work documented here.

About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine. This article was updated in May 2026.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

Access her work on Pubmed, Google Scholar, ResearchGate and ORCID.

Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care

www.drshibalbhartiya.com
 +91 88826 38735

1500+ Five Star Patient Reviews Google Business Profile

Upload your reports for a structured review.

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation for glaucoma

Glaucoma Second Opinion in Gurgaon

Glaucoma second opinions in Gurgaon focus on confirming diagnosis, reassessing risk, and ensuring the treatment plan is appropriate for long-term vision protection. With Dr Shibal Bhartiya, the goal is careful evaluation, not escalation, often refining than increasing treatment.

A glaucoma second opinion is essential when diagnosis is unclear, treatment is escalating, or vision feels different despite normal reports.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google. If you’re considering a glaucoma second opinion in Gurgaon, the goal isn’t more tests—it’s clearer understanding of risk, stability, and what actually needs to be done next.
A thoughtful review can distinguish true progression from noise, helping you avoid both over-treatment and missed change.

Glaucoma Second Opinion in Gurgaon: Clear Answers, Long-Term Vision Protection

Many people come for a glaucoma second opinion in Gurgaon and NCR (from across Delhi NCR; South Delhi, Faridabad, and Noida) not because something dramatic happened, but because something doesn’t feel clear. This page is designed as a patient education resource to help people understand when an independent glaucoma review may be useful. Many patients simply need reassurance and clarity rather than change in treatment. If you’ve been told you have glaucoma, or might have it, and something doesn’t feel clear, this page is for you. Why patients seek a second opinion: • Diagnosis feels unclear • Treatment is escalating • Reports don’t match symptoms • They want to avoid unnecessary intervention A test result that was explained too quickly, or not at all. Drops started without explanation. Different doctors saying different things. “Watch and wait” without explaining the risk. Or simply the feeling that something important may be getting missed. Glaucoma is not a disease of sudden events. It is a disease of small decisions repeated over years. And that is exactly why a thoughtful second opinion with a glaucoma specialist matters. Known for her structured approach to glaucoma risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinions for patients seeking clarity before major treatment decisions. Both, in person, and online. You might want to hear Dr Bhartiya talk about glaucoma here.

Why Glaucoma Needs Careful Re-Evaluation

Glaucoma is often called a silent disease. But what makes it truly difficult is something deeper: Damage happens slowly, invisibly, and often irreversibly. Many patients see clearly on the chart and are told everything is fine. Yet subtle loss in contrast, low-light vision, reading comfort, or navigation confidence may already be happening. Routine eye exams can miss glaucoma. Single test results can mislead. Normal eye pressure does not rule it out. Cataract surgery does not protect against it. A second opinion  from a glaucoma specialist is not about doubting your doctor. It is about protecting your long-term vision.

When Should You Seek an Independent Glaucoma Second Opinion?

You may benefit from one if:
  1. You were diagnosed suddenly and don’t understand why
  2. Different doctors gave different advice
  3. You were told you are a glaucoma suspect, to “watch and wait” without clarity
  4. You are on multiple drops and unsure if risk is controlled
  5. Your visual field or OCT reports are confusing
  6. You have family history of glaucoma
  7. You have high eye pressure but normal tests
  8. You had cataract surgery but glaucoma risk persists
  9. You are worried about progression
  10. When surgery is suggested but you want to understand timing
  11. When tests look stable but vision feels different
  12. When treatment is increasing but clarity is not
  13. When you want long-term risk explained, not just current numbers
Many people seek second opinions simply for reassurance. Or to understand their Visual field and OCT reports. That is completely reasonable. Dr Bhartiya has reviewed glaucoma diagnoses from across India, including patients who were overtreated, undertreated, or misclassified as suspects without adequate follow-up. That said, many second opinions do not result in treatment changes. Often, they simply help patients understand risk, timelines, and what truly needs attention.

What Makes Independent Glaucoma Second Opinions Different

A true second opinion is not repeating the same test. It is about risk stratification. In glaucoma, we ask:
    1. What is your lifetime risk of vision loss?
    1. How fast is the disease likely to progress?
    1. What happens if we do nothing for 10 years?
    1. Are we treating numbers or protecting function?
    1. Are tests consistent over time? And progression of disease?
These questions change management more than any single scan. Glaucoma is a neurodegenerative disease affecting the optic nerve. The goal is not just lowering pressure- it is protecting brain-eye function over the long arc of life. Therefore, the focus is on:

• Independent interpretation of OCT and visual fields
• Looking for progression patterns rather than single reports
• Identifying treatment escalation that may not add benefit
• Identifying under-treatment when risk is underestimated
• Clarifying whether surgery timing is appropriate

The goal is not to replace your treating doctor. The goal is to make sure the long-term direction of care is clear.

Dr Bhartiya’s second opinion is structured around lifetime risk, not single numbers: a framework built on 25 years of subspecialty glaucoma practice and peer-reviewed research

What Happens in a Structured Glaucoma Second Opinion

A proper independent glaucoma second opinion includes six steps.

1. History and Symptom Review

We discuss subtle symptoms that routine exams miss: contrast loss, reading fatigue, night driving discomfort see clearly. Because patients often compensate without realising.

2. Test Interpretation

Not just repeating tests, but understanding them: • OCT scans • Visual fields • Optic nerve photos • Eye pressure trends • Corneal thickness Tests in isolation can mislead. Patterns over time tell the truth.

3. Risk Assessment

We assess your risk based on: • age • family history • optic nerve structure • field changes • pressure behaviour • general health Two patients with identical pressure may have very different risk.

4. What Is Target Eye Pressure?

Target eye pressure (Target IOP) is the eye pressure level that is likely to keep your glaucoma stable over your lifetime. It is not the same for every patient. Your target is decided based on your optic nerve health, visual field changes, age, rate of progression, and overall risk of vision loss. Two people with the same pressure may need different targets. Importantly, the goal of treatment is not just to lower a number, but to protect the optic nerve and preserve useful vision for the long term. Your target pressure may change over time as new information becomes available, which is why regular follow-up is essential. Dr Bhartiya’s seminal work on Target IOP is referenced by glaucoma specialists globally.

5. Management Options Explained Clearly

If treatment is needed, options are explained calmly: Observation – when safe Drops – when effective and necessary Laser – when appropriate Surgery – when risk demands it More drops do not always mean better care. Timing matters more than quantity.

6. Long-Term Plan

A clear follow-up plan reduces anxiety: How often to test. What changes matter. When to escalate treatment. What symptoms to watch. What tests show glaucoma progression. Clarity reduces fear, and improves long term outcomes. A second opinion with Dr Bhartiya is not a repeat of your last appointment. It is a structured review of your lifetime glaucoma risk: built on 94 peer-reviewed publications, 25 years of subspecialty practice, and a patient-centred approach to long-term vision protection

Common Myths About Glaucoma

“My vision is 6/6, so I am fine.”

Many glaucoma patients read the chart perfectly until late stages. Seeing clearly is not the same as seeing safely.

“My eye pressure is normal.”

Normal-tension glaucoma exists. Structure matters more than numbers.

“Cataract surgery fixed my glaucoma.”

Cataract surgery may lower pressure slightly, but it does not cure glaucoma.

“More drops mean stronger treatment.”

Sometimes fewer, well-timed treatments protect vision better.

“If nothing changed in one year, I’m safe.”

Glaucoma progression often becomes obvious only in retrospect. Early care prevents late regret.

Why Early, Boring Care Matters

Healthcare systems often reward dramatic surgery and late intervention. But glaucoma is different. It rewards: • early detection • consistent follow-up • careful interpretation • patient education • steady treatment This is quiet work. But it saves vision. Many patients who lose sight from glaucoma did everything they were told—they were simply diagnosed too late or monitored incorrectly. Glaucoma second opinions help prevent that.

What to Bring for Your Glaucoma Second Opinion

Don’t worry if you don’t have everything. Come anyway — we will work with what you have. But if you have your records, please remember to bring: • OCT reports • Visual field reports • Previous prescriptions • Eye pressure records • Any optic nerve photos • Medical history Even reports from many years ago help understand progression. If you don’t have them, we can still help, but more data improves clarity.

Patient-Friendly Explanation Is Essential

A good second opinion should leave you feeling calmer, not more confused. You should understand: • your diagnosis • your risk • your options • your timeline If you leave with clarity, the consultation was successful, even if the advice is simply reassurance and the same as the first doctors’. Over 1,500 patients have rated their consultation five stars on Google. Read their experiences before your visit If you want to understand your condition better before deciding: If you want to understand your condition better before deciding: Explore patient-friendly explanations here

A Note on Ethics

A second opinion is not about doubt. It is about clarity before irreversible decisions. Seeking a second opinion is not disrespectful to your current doctor. It is responsible healthcare. Glaucoma decisions affect vision irreversibly. Patients deserve clarity. And often, the second opinion confirms the first and strengthens confidence in your care.

Frequently Asked Questions

1. Why should I take a glaucoma second opinion if my vision is normal?

Many people with glaucoma read the eye chart perfectly until late stages. Early glaucoma affects contrast, low-light vision, and visual safety before clarity. A second opinion helps assess long-term risk, not just current vision.

2. Does a glaucoma second opinion mean my first doctor was wrong?

Not at all. Glaucoma care often has more than one reasonable approach. A second opinion helps confirm diagnosis, clarify risk, and ensure that treatment timing is right for your lifetime vision protection.

3. What reports should I bring for a glaucoma second opinion?

Please bring OCT scans, visual field reports, optic nerve photos, prescriptions, and eye pressure records. Even old reports are useful because glaucoma diagnosis depends on trends over time, not single tests.

4. Can glaucoma be missed in routine eye checkups?

Yes. Routine exams focused on glasses or cataract may not detect early glaucoma. Optic nerve evaluation, visual fields, and OCT are needed to detect subtle structural damage before symptoms appear.

5. If my eye pressure is normal, can I still have glaucoma?

Yes. Normal-tension glaucoma is common. Eye pressure is only one risk factor. Optic nerve structure, visual fields, family history, and progression over time are equally important.

6. I was told to “watch and wait.” Is that safe?

Sometimes observation is appropriate, but it should be based on careful risk assessment. A second opinion can help determine whether observation is safe or whether early treatment would better protect vision.

7. Will I need to repeat all tests during a second opinion?

Not always. Often, existing tests can be carefully interpreted to understand patterns. Additional tests are only recommended if needed for clarity or if previous data is incomplete.

8. Can a glaucoma second opinion be done online?

Initial review of reports can often be done through teleconsultation. However, a full clinical evaluation may be needed in some cases to assess optic nerve structure, pressure variation, and risk accurately.

9. How do I choose a glaucoma specialist in Gurgaon or NCR?

Look for a fellowship trained glaucoma specialist who focuses on early diagnosis, clear communication, and long-term monitoring of glaucoma progression. Look for a glaucoma doctor who is known for ethical, patient-centred glaucoma care and independent second opinions. You may want to read through their google reviews as well, to see what their patients say about explanations, communication skills and patient centricity.

How to Book a Glaucoma Second Opinion

Consultations in person are ideal. If you can come over for a glaucoma second opinion in Gurgaon. Patients travel from across North India, including Delhi NCR (especially South Delhi, Faridabad, and Noida) for independent glaucoma consultations in person with Dr Shibal Bhartiya. If you can’t, a teleconsult may help. To prepare a structured review, please fill the second-opinion form on the website before your appointment. Appointments: +91 88826 38735 Website: drshibalbhartiya.com

Glaucoma Second Opinion Checklist

What to Prepare Before Your Appointment

A structured second opinion is most helpful when we can see your history clearly. Please bring as many of these as possible.

1. Eye Test Reports

Please bring all reports, even old ones. • OCT scans (both eyes) • Visual field reports • Optic nerve photos • Eye pressure readings • Pachymetry (corneal thickness) • Gonioscopy report if available Old reports are very valuable because glaucoma diagnosis depends on change over time, not single tests.

2. Medication Details

Bring: • All eye drops you are using • Previous drops you had used, allergies if any • How long you used each drop • Any side effects you noticed If possible, take a photo of your drops before coming. This helps us understand whether treatment is adequate and sustainable.

3. Medical History

Please tell us if you have: • Diabetes • Blood pressure problems • Thyroid disease • Migraine • Sleep apnea • Steroid use (tablets, inhalers, skin creams) These conditions can influence glaucoma risk.

4. Family History

Tell us if any family members had: • Glaucoma • Blindness of unknown cause • Long-term eye drop use Glaucoma often runs in families.

5. Symptom Notes

Even if vision feels normal, write down if you notice: • Difficulty in dim light • Trouble with stairs or navigation • Reading fatigue • Glare at night • Feeling slower visually These subtle symptoms help guide risk assessment.

6. Questions You Want Answered

Write your questions before coming. Examples: Do I really have glaucoma? What is my lifetime risk? Are my drops necessary? Can I stop treatment safely? How often should I test? A second opinion should leave you with clarity.

7. Glasses and Previous Prescriptions

Bring your current glasses and older prescriptions if available. Changes in power can sometimes give useful clues.

8. If You Don’t Have Reports

Please don’t worry. Come anyway. We can repeat tests if needed. The goal is clarity, not paperwork perfection.

Before Your Appointment

• Sleep well if possible • Continue your eye drops unless told otherwise • Bring someone with you if you feel anxious • Allow enough time for discussion Glaucoma decisions should not be rushed.

Closing Thought

Glaucoma does not usually cause pain. It does not usually cause sudden blindness. It quietly narrows life over years if missed. The goal of a glaucoma second opinion is not fear. It is clarity. Early, calm, stabilising clarity in a system that often reacts late. If you are unsure, anxious, or confused about your glaucoma diagnosis, a thoughtful review can protect something precious: your future vision, and your quality of life.

Read the Research Articles

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine. This article was updated in April 2026. She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes. As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics. Access her work on Pubmed, Google Scholar, ResearchGate and ORCID. Dr Shibal Bhartiya Glaucoma • Second Opinion • Advanced Care www.drshibalbhartiya.com +91 88826 38735 1500+ Five Star Patient Reviews Google Business Profile Upload your reports for a structured review. If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation for glaucoma Related Reading Get an Online Glaucoma Consult Visual Field and OCT: Structure & Function Correlation Glaucoma Diagnosis in Gurgaon Glaucoma Progression: What It Means and How to Slow It Glaucoma treatment in Gurgaon All About Glaucoma Medication Glaucoma Lasers: SLT & LPI Glaucoma surgery in Gurgaon MIGS in Gurgaon Get a Glaucoma Second Opinion in Gurgaon

What Good Glaucoma Care Actually Optimises For

Posted on by Dr Shibal Bhartiya

Good glaucoma care optimises for long-term preservation of vision, not just short-term control of eye pressure. It focuses on early…